SCHEMBL2676260

SCHEMBL2676260

CC1CCN(Cc2c(C(=O)O)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.45
HRH3 Q9Y5N1 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 4/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
ALOX15 P16050 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPK1 P28482 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
SHMT2 P34897 1/20 0.40
TSHR P16473 1/20 0.40
LMNA P02545 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677338 0.89 USP14 (0.41) NPSR1MEN1KMT2AL3MBTL1MAPK1
SCHEMBL2675162 0.88 MEN1 (0.38) NPSR1MEN1KMT2AL3MBTL1MAPK1
SCHEMBL2676567 0.88 KMT2A (0.42) HRH3HTTNPSR1ALDH1A1HSD17B10
SCHEMBL2676543 0.87 NPSR1 (0.39) HTTNPSR1MEN1KMT2AL3MBTL1
SCHEMBL2676251 0.87 DRD4 (0.44) ALDH1A1KDM4EMEN1KMT2ADRD2
SCHEMBL2676758 0.87 HRH3 (0.46) HRH3NPSR1ALDH1A1KDM4EALOX15
SCHEMBL2676392 0.87 MAPK1 (0.45) ACHEHTTNPSR1ALDH1A1KDM4E
SCHEMBL2675569 0.87 ALDH1A1 (0.46) ACHEHRH3HTTNPSR1ALDH1A1
SCHEMBL2676686 0.86 SLC2A1 (0.45) SMN1; SMN2KMT2ADRD2DRD4DRD3
SCHEMBL2675780 0.86 ALDH1A1 (0.48) HRH3HTTNPSR1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 ACHE 2978/4885HRH3 762/4885HTT 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.